

ImpediMed Limited
Unit 31C, 12-18 Tryon Road
Lindfield
NSW 2070
Australia

E: investorrelations@impedimed.com

W: impedimed.com

2 October 2025

Companies Announcements Office
Australian Securities Exchange

Major US health insurer publishes positive coverage for BIS Lymphedema Assessment

ImpediMed Limited (ASX: IPD) (**ImpediMed** or the **Company**) is pleased to announce one of the largest health insurers in the United States has issued positive coverage for CPT Code 93702, recognising bioimpedance spectroscopy (BIS) as medically necessary for the assessment of lymphedema. This decision supports reimbursement for lymphedema testing using ImpediMed's SOZO® Digital Health Platform and represents a significant step forward in our mission to prevent breast cancer-related lymphedema.

As the largest customer-owned insurer in the United States, and licensee of Blue Cross Blue Shield Association in 5 states, they provide access to care nationwide through plans in Illinois, Montana, New Mexico, Oklahoma and Texas. They rank as the fifth largest health insurance provider in the United States with a stated mission of expanding access to high-quality care for their members.

This is a positive development for breast cancer survivors across the United States. These additional insurance coverage for lymphedema assessment using bioimpedance spectroscopy (BIS), means more than 86% of all US patients are now reimbursed for their treatment. This expanded access means that millions of patients can benefit from earlier detection and more accurate monitoring of lymphedema—one of the most common and debilitating side effects following breast cancer treatment. Early identification through BIS allows for timely intervention, helping to prevent progression to more severe stages of lymphedema, reduce long-term complications, and improve overall quality of life. For survivors, this coverage expansion represents not just broader access to care, but a meaningful step toward proactive, preventative health management and peace of mind during recovery.

The announcement adds to the recent momentum in insurance coverage, representing an additional sixteen million covered lives and bringing total reimbursed coverage for lymphedema testing using ImpediMed's SOZO® Digital Health Platform SOZO to over 301 million covered lives and 86% coverage nationwide. Importantly it takes another 5 states above 80% coverage with 3 of those over 90%. Included in the five states are 2 of the 5 largest population States in the US in Texas and Illinois. We expect these changes, together with those announced in the Q4 FY25 Quarterly Results, to have a meaningful effect for commercialisation of SOZO.

Dr Parmjot Bains Managing Director of ImpediMed commented "During my US travels, I consistently meet dedicated clinicians who are eager to integrate SOZO into their patient care pathways. In today's financially constrained healthcare environment, hospitals face a difficult balancing act—managing tight budgets while striving to deliver the best possible clinical outcomes. Decisions from major insurance companies to recognise the medical necessity of using bioimpedance spectroscopy (BIS) for lymphedema assessment are pivotal. These greatly enhance the commercial feasibility of

implementing a SOZO-based lymphedema prevention program across many hospital systems and progress toward our goal: ensuring every cancer patient at risk of lymphedema has access to prospective surveillance through SOZO.”

Approved for release by the CEO and MD of ImpediMed Limited.

For more information, contact ImpediMed Investor Relations at investorrelations@impedimed.com.

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed’s SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward looking statements

This announcement contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited).